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health care claims database and the claims and medical charts for a subset of this 
population were reviewed to extract information pertaining to disease-modifying 
therapy, corticosteroid therapy, MS-related procedures, and diagnosis and relapse 
dates. The agreement between the data sources for each type of information was 
identiﬁed. RESULTS: From a total population of 11,326 MS patients in the claims 
database, 300 had their medical records reviewed. Among patients with claims for 
glatiramer acetate (n = 68), 95.6% also had it indicated in their charts. Claims agreed 
with charts for 91.8% of patients with a claim for intramuscular interferon β-1a (n = 
85), 81.8% of patients with a claim for subcutaneous interferon β-1a (n = 55), and 
87.5% of patients with a claim for interferon β-1b (n = 48). Methylprednisolone was 
the most commonly indicated corticosteroid in both data sources, and among patients 
with evidence of a methylprednisolone ﬁll in the claims (n = 114), 66.7% also had a 
prescription indicated in their chart. Most patients with claims-based evidence of 
MS-related procedures also had them indicated in their charts: 71.0% with MRI, 
81.0% with lumbar puncture, and 66.7% with evoked potential testing. For both 
diagnosis and relapse dates, at least half of the patients had perfect agreement. CON-
CLUSIONS: Claims and medical charts provide complementary information with a 
degree of overlap. Claims appear to approximate chart data with regard to certain 
MS-related variables, such as dates and disease-modifying therapy, but the data 
sources also provide unique information which might be differentially suited to 
addressing diverse research questions.
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A CASE STUDY
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OBJECTIVES: Since its development in the 80’s, variations of the Alzheimer’s Disease 
Assessment Scale-Cognitive subscale (ADAS-Cog), a Clinician-Reported Outcome 
(ClinRO) measure, have been used to monitor disease progression and treatment 
efﬁcacy in Alzheimer’s disease. The objective of this study was to identify all versions 
used as a basis for translation in Mapi Institute projects and to take stock of existing 
translations. METHODS: The review was based on all ADAS-Cog translation projects 
performed by Mapi Institute. RESULTS: Sixteen projects were identiﬁed representing 
a total of 70 languages and 219 translations. Translations were based on 11 source 
versions which differed in terms of content (number of items, order of items and 
instructions), and format. The number of items ranged from 11 to 15. Four studies 
used 13 items, but only in two cases the same items were used but in a different order. 
Four studies used 12 items: only two studies used the same items (with a different list 
of words for the Word Recognition Task), but again in a different order. Format and 
instructions differed in all cases. In most projects the source version provided by the 
sponsor was a single document mixing instructions with the rater and response forms. 
Only in 3 cases the original consisted in a separate instruction manual and response 
forms. With regard to available translations, more than one translation was identiﬁed 
in 56 of the 70 available languages and in one language as many as 7 translations. 
CONCLUSIONS: The abundance of different versions of the same questionnaire both 
in its original US English form as in translation makes comparisons between studies 
or pooling of data difﬁcult for both researchers and users. In the light of FDA’s recent 
PRO guidance it would be beneﬁcial to demand the same scientiﬁc rigor when using 
ClinROs in international studies.
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THE EFFECT OF MULTIPLE COMPARISONS ADJUSTMENTS IN 
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OBJECTIVES: Explore the effect of adjusting for multiple comparisons in analyzing 
outcome variables between more than two strata. METHODS: Health-related quality 
of life (HRQoL) via SF-12 Health Survey was measured at baseline for 191 patients 
in a U.S. multiple sclerosis observational study. HRQoL was summarized in two 
continuous variables: Physical Component Score (PCS-12) and Mental Component 
Score (MCS-12). Patient work status was expressed by one categorical variable with 
four values: Working Full-time (W), Working Part-time (WP), Not Working due to 
MS (NW-MS), Not Working due to other reasons (NW). Generalized linear models 
were used to measure the overall association HRQoL and work status. Pairwise 
comparisons were conducted between the HRQoL means with respect to each of the 
four categories of work status. The Bonferroni method was used to control the fami-
lywise error rate under multiple comparisons test. RESULTS: Overall association 
between Work Status and HRQoL was statistically signiﬁcant (p-values: <.001 for all 
measures), suggesting that HRQoL differs by work status. Pairwise comparisons 
showed that only the NW-MS group was statistically signiﬁcantly different from all 
other groups (all p-values <.001) in PCS-12 and different from W and WP groups in 
MCS-12 (p-value: W = 0.03, WP = < .001), while all other comparisons were not 
signiﬁcantly different from each other. If the Bonferroni adjustment is not applied, the 
pairwise comparisons lead to more differences being signiﬁcant (p-value: W vs WP = 
0.04 in PCS-12 and MCS-12). CONCLUSIONS: Even though the overall association 
between two variables may be statistically signiﬁcant, if the categorical variable has 
more than two categories, then applying multiple comparisons adjustments to all 
pairwise comparisons more appropriately tests the statistical signiﬁcance of the differ-
ences between these individual categories. Neglecting to account for the fact that 
multiple comparisons are being made may lead to erroneous conclusions about dif-
ferences in outcomes.
SENSORY SYSTEMS DISORDERS – Clinical Outcomes Studies
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OBJECTIVES: To evaluate evidence on effectiveness of intravitreal Avastin for neo-
vascular age related macular degeneration (AMD). METHODS: We searched the 
Medline database for articles on bevacizumab for neo-vascular AMD, published 
between January 1, 2005 and September 1, 2009. The search criteria were English 
language manuscripts, human studies and search terms “bevacizumab”, “Avastin”, 
“age-related macular degeneration”, “ARMD”, “AMD”,”intra-vitreal” as a major 
heading. Boolean operators were used to combine the search terms. Studies in which 
primary outcome measures were visual acuity (VA) and central retinal thickness (CRT) 
were included for review. Two reviewers independently selected studies, assessed 
methodological quality using Scottish Intercollegiate Grading Network (SIGN) system. 
RESULTS: Overall, there were 520 citations, of which only 216 were relevant after 
title and abstract screening. Sixty-seven manuscripts were ﬁnally included for review, 
of which three were systematic reviews, three were randomized Controlled Trials 
(RCT), 49 were pre-post/ non-randomized studies and 13 were studies on safety and 
adverse effect. Three RCTs show bevacizumab to be more effective than PDT (with 
or without triamcinolone). However, these RCTs had several methodological issues; 
evidence from these RCT’s was of moderate quality. Several pre-post and non-ran-
domized studies have also suggested the effectiveness of bevacizumab, but these studies 
had several design limitations and hence the quality of evidence was deemed poor. 
Pooled outcome estimates, showed bevacizumab therapy,on average, improved VA by 
nine EDTRS letters and reduced CRT by 90 μm. Incidence of adverse events was low, 
similar to ranibizumab. Currently moderate (grade B) to poor quality of evidence is 
available in support of bevacizumab for neo-vascular AMD. CONCLUSIONS: Based 
on current evidence (grade B) off-label Intravitreal bevacizumab seems to be safe and 
effective for the treatment of neo-vascular AMD in the short term, especially for 
underserved and ﬁnancially challenged communities.
SENSORY SYSTEMS DISORDERS – Cost Studies
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RETURN ON INVESTMENT OF ABLATIVE FRACTIONAL LASERS
Jutkowitz E
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OBJECTIVES: Conduct a return on investment (ROI) analysis of 8 ablative fractional 
lasers used for cosmetic facial plastic surgery from the perspective of a facial plastic 
surgeon. METHODS: We identiﬁed 8 of the largest (based on sales volume) ablative 
fractional lasers for this analysis. ROI is (ΣTotal Revenue–ΣTotal Cost)/(ΣTotal Cost) 
and is deﬁned as the additional dollar returned from each dollar invested. Revenue 
was estimated as price per procedure multiplied by total number of procedures in a 
year. Total cost is a composite of purchase price and operating costs. In the base case 
analysis two purchase options were assumed 1) a 5 year lease with a $0 down payment 
and 2) a 3 year lease with a $0 down payment. In addition to monthly lease payments, 
included in the total cost estimate were service contracts, labor costs, and disposables. 
Sensitivity analyses were preformed to account for variability in cost and revenue 
assumptions. RESULTS: Revenue for each laser was estimated to be $51,072/year. 
Under a 5 year lease, the assumed total cost of each laser ranged from $115,827–
$240,597. This is compared to the total cost under a 3 year lease of each laser which 
ranged from $74,364–$124,878. Average ROI under the 5 year lease term was .54 
and ROI varied between −.03 (most expensive laser) and 1 (least expensive laser). The 
average 3 year ROI was .08, and ROI varied between -.35 (most expensive laser) and 
.38 (least expensive laser). CONCLUSIONS: Based on the assumptions of our analysis 
the laser with highest ROI was the least expensive laser. While ROI is an important 
ﬁnancial it should not be the sole means by which to determine a purchase. Physicians 
must also consider the clinical effectiveness of each laser and their own clinical judg-
ment when making such decisions.
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OBJECTIVES: Evaluate the annual cost of Dry Eye Diseases (DED) care in the United 
States from both a societal and a payer’s perspective METHODS: A decision-tree 
model was developed to estimate the annual cost for managing a cohort of DED 
patients with differing severity of symptoms and treatments utilizing data collected 
from survey and the literature. The direct costs included over the counter (OTC) 
medications, cyclosporine, punctal plugs, physician visits, and nutrition complements. 
The indirect costs were computed based on the self-reported productivity loss includ-
ing absenteeism and presenteeism. Multiple-one way sensitivity analysis was employed 
to evaluate the impact of changes in parameters within their 95% conﬁdence intervals 
on the cost estimate. RESULTS: In the base-case analysis, the total mean annual direct 
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cost of managing a dry eye patient was $783 in the US from the payers’ perspective, 
with $678, $771, and $1267 for mild, moderate, and severe patients separately. The 
overall direct costs of DED for the health care system was $3.84 billion based on the 
prevalence of DED. The average annual direct cost for self-treated patients using OTC 
treatment or nutritional supplements was estimated as $126 per patient. The annual 
productivity loss per full-time worker with DED ranges from $12, 569 to $18,168 
depending on the severity of symptoms. The sensitivity analysis suggested that the 
estimated mean direct cost per DED patient seeking professional medical care ranges 
from $757 to $809 approximately. Multiple one-way sensitivity analysis suggested 
the cost estimate was most sensitive to the variation in the distribution of severity of 
symptoms, the frequency of ophthalmologist visits, prevalence of the combined use of 
punctal plugs and cyclosporine, the frequency of optometrist, and compliance with 
cyclosporine by severe patients. CONCLUSIONS: DED poses a substantial amount 
of economic burden for the payer and the society with the indirect costs substantially 
outweighing the direct costs.
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OBJECTIVES: To determine the cost-effective threshold price of the AcrySof Cachet 
phakic intraocular lens (PIOL) relative to the currently marketed Visian and Artisan 
PIOLs in the US. METHODS: We developed a Markov cost-effectiveness model that 
compared the Cachet to the Visian and Artisan PIOLs in a hypothetical cohort of 
patients with moderate to high myopia. A payer perspective was adopted. Costs and 
effectiveness results were discounted at 3% over a 40 year time horizon. Effectiveness 
was expressed as vision adjusted life years (VALYs). VALYs represent a quantiﬁcation 
of the beneﬁts derived from various levels of visual acuity (VA) accumulated over time. 
VA outcome probabilities were taken directly from the CE Mark (Cachet) and FDA 
approved PIOL product labels. The prices of the Visian and Artisan PIOLs were $750 
and $695 respectively. Patients with less than 20/20 VA were assumed to require either 
glasses and/or contact lenses. PIOL, contact lenses and eye glasses costs were based 
on 2009 data from MarketScope and the Vision Watch Report. Probabilities for 
adverse events and associated procedures were derived from PIOL product labels and 
physician interviews. Surgical and drug costs were estimated using reference based 
physician fee estimates and the Medi-Span Price Rx database. Uncertainty was 
addressed through univariate and probabilistic sensitivity analysis (PSA). RESULTS: 
The base-case cost-effectiveness model indicated that the Cachet PIOL economically 
dominated the Visian PIOL up to a threshold price of $1587, and the Artisan PIOL 
up to a threshold price of $2373. The PSA showed that at these prices, the probabilities 
that the Cachet dominated were 59% and 63% respectively. CONCLUSIONS: Given 
its greater efﬁcacy and favourable adverse events proﬁle, the Cachet PIOL was eco-
nomically dominant up to a price twice that of the Visian PIOL and three times that 
of the Artisan PIOL with a considerable degree of certainty.
PSS5
COST-EFFECTIVENESS STUDY ON THE USE OF TERBINAFINE VS. 
ITRACONAZOLE IN THE TREATMENT OF ONYCHOMYCOSIS IN 
MEXICO: AN INSTITUTIONAL PERSPECTIVE BASED ON THE RESULTS 
OF THE L.I.O.N. STUDY
Briones B, Garcia F
Novartis Farmaceutica, Mexico City, DF, Mexico
OBJECTIVES: To examine whether terbinaﬁne or itraconazole is a more cost-effective 
treatment for onychomycosis in an institutional setting in Mexico. METHODS: A 
cost-effectiveness analysis was designed; a decision tree with bayesian approach was 
used to model the cost-effectiveness of terbinaﬁne vs. itraconazole in the treatment of 
onychomycosis in Mexico. The perspective was from the Mexican Institute of Social 
Security (IMSS). Discount rate was not used because the time horizon was less than 
1 year. Resource use data was taken from IMSS. Cost data for medications was 
obtained from a local drug distributor database (NADROSA Aug 2009), assuming 
terbinaﬁne dosing scheme as 250 mg daily for 3 months, and itraconazole dosing 
scheme as 400 mg daily for 7 days every 4 weeks for 3 months (pulse dosing scheme). 
Cost data for physician consult was estimated as a ﬁxed-variable. As this analysis was 
performed from an institutional perspective, no other costs were identiﬁed to be 
required for the treatment of onychomycosis. Using data from the L.I.O.N. clinical 
study, mycological cure success rates were estimated for both treatments as ﬁrst 
options; for mycological cure failures, re-treatment costs were estimated using a second 
terbinaﬁne scheme in both groups and an additional physician consult. Total costs per 
patient were determined and incremental cost-effectiveness ratios were calculated. A 
Monte Carlo (100,000 iterations) simulation was performed to reduce the error <0.03. 
A probabilistic sensitivity analysis was performed. RESULTS: The incremental cost 
analysis revealed a total cost of $3823 for terbinaﬁne vs. $7152 for itraconazole (both 
in Mexican pesos, p < 0.001) per patient successfully treated. Terbinaﬁne provides 
superior total health beneﬁts than itraconazole regardless of willingness to pay. The 
sensitivity analysis conﬁrmed the robustness of the model. CONCLUSIONS: From an 
institutional perspective, terbinaﬁne is a more cost-effective (dominant) choice than 
itraconazole for treating onychomycosis in Mexico.
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THE COST-EFFECTIVENESS OF ISOTRETINOIN IN PATIENTS WITH 
MODERATE-TO-SEVERE ACNE VULGARIS
Shin J, Hay J
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OBJECTIVES: To assess from a societal perspective whether isotretinoin (13-cis-ret-
inoic acid) or oral antibiotics in combination with topical preparations is the more 
cost-effective ﬁrst-line treatment of moderate-to-severe acne vulgaris. METHODS: A 
decision-tree model was used to simulate therapy costs and effectiveness. All estimates 
of cost and effectiveness were obtained from the literature or expert opinion. The 
cost-effectiveness ratio was reported as incremental cost per quality-adjusted life-year 
(QALY) gained. The time horizon was 2 years. Costs and QALYs were discounted by 
a monthly rate of 0.0025%, which is equivalent to an annual rate of 3%. All costs 
were adjusted to 2009 US dollars. A one-way sensitivity analysis was used to determine 
the robustness of the model’s results. The model was developed using Microsoft Excel. 
RESULTS: Isotretinoin increases discounted costs by $1,486 and discounted QALYs 
by 0.071 years when compared to conventional therapy of oral antibiotics and topical 
preparations. This resulted in an incremental cost-effectiveness ratio (ICER) of 
$20,930 per QALY gained for the base case. The results of the model were insensitive 
to most model parameters except for the probabilities associated with achieving 
adequate response or relapse while on therapy. The biggest change in the ICER (204% 
increase) was caused by a 17% increase in the probability of maintaining adequate 
response (no relapse) with conventional therapy. Although the ICER was sensitive to 
these probability values, the highest ICER value of $63,602/QALY found from the 
sensitivity analysis was still below the threshold for cost-effectiveness. CONCLU-
SIONS: Isotretinoin was more costly and also more effective than conventional 
therapy. These results did not change when model parameters were varied in the 
sensitivity analysis. Assuming a $120,000/QALY threshold for cost-effectiveness, 
isotretinoin was cost-effective in the ﬁrst-line treatment of moderate-to-severe inﬂam-
matory acne.
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OBJECTIVES: Glaucoma, a chronic disorder that requires lifelong treatment, creates 
a ﬁnancial burden on patient and health care payers. This study compared ﬁxed-
combination therapies in patients with open-angle glaucoma, namely, Latanoprost 
with Timolol (LT), Dorzolamide with Timolol (DT), and Brimonidine with Timolol 
(BT). METHODS: A cost effectiveness analysis was conducted by extracting data from 
published literature and primary data collected from pharmacy stores. The study was 
conducted from a managed care perspective with drug utilization for a period of 12 
months. A decision analytic model was developed and incremental cost-effectiveness 
ratios (ICER) were calculated. Therapy cost was calculated by considering medication 
cost (by taking an average reimbursement amount provided by Medicare part D and 
private insurances), physician visit cost, cost associated with adverse drug events, and 
cost due to lack of patient persistency (based on expected annual drug usage). Effec-
tiveness measure considered was percent reduction in intraocular pressure (IOP) from 
baseline. A one-way sensitivity analysis was performed by varying cost by 25% to 
take into consideration the potential wastage, overutilization, underutilization, and 
various differences in IOP reduction in patients. RESULTS: Mean average percent IOP 
reduction for LT, DT and BT was 6.3%, 4.3% and 4.6%, respectively. The total cost 
of therapy for LT, DT and BT was estimated to be $711, $935, and $1099, respec-
tively. ICER analyses indicated a gain of $111.5 for change from DT to LT, while a 
change from BT to LT indicated a gain of $228. The results remained robust after 
sensitivity analysis. CONCLUSIONS: In our study, LT was found to be more cost-
effective compared to DT and BT. Managed care payers may wish to prioritize ﬁxed-
combination therapies used for glaucoma considering medication related adverse 
events and persistency. Further, research taking into account various other costs 
should be conducted to provide better evidence.
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OBJECTIVES: Psoriasis is a chronic and incurable systemic inﬂammatory disease with 
devastating impact on overall health of patients. Ustekinumab, a fully human mono-
clonal antibody, is the ﬁrst treatment to speciﬁcally target IL-12 and IL-23.The efﬁcacy 
and safety of ustekinumab have been studied in three Phase III, international, ran-
domised, controlled clinical trials and its clinical superiority over etanercept was 
demonstrated in a Phase III trial (ACCEPT). The objective of this study was to 
compare cost efﬁcacy of subcutaneously administered biologics by using a cost per 
responder model in Turkey. The study was undertaken from a Turkish health care 
payer perspective. METHODS: In the cost per responder model, clinical efﬁcacy was 
measured by improvement in the Psoriasis Area and Severity Index (PASI 75 response) 
from randomized, controlled trials. An indirect comparison using a Mixed Treatment 
Comparison (MTC) meta-analysis was used to estimate response rates. Comparators 
used in the model were ustekinumab, etanercept, adalimumab, and efalizumab. 
Ustekinumab efﬁcacy has been analyzed based on patient’s weight for patients with a 
